Opthea Ltd (OPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Opthea Ltd (OPT) has a cash flow conversion efficiency ratio of 0.460x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-92.00 Million ≈ $-65.10 Million USD) by net assets (AU$-200.16 Million ≈ $-141.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Opthea Ltd to measure how much of total assets are equity-financed.
Opthea Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Opthea Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Opthea Ltd (OPT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Opthea Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Opthea Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wooree Lighting Co.Ltd
KQ:037400
|
-0.060x |
|
Seker Finansal Kiralama AS
IS:SEKFK
|
0.184x |
|
HANHUA FNCL HLDG CO.H YC1
F:5HF
|
N/A |
|
KB SPAC 6
KQ:208640
|
-0.119x |
|
Titanium Sands Ltd
AU:TSL
|
-0.031x |
|
Creative Media & Community Trust Corporation
NASDAQ:CMCT
|
-0.101x |
|
Electronic City Indonesia Tbk
JK:ECII
|
-0.015x |
|
Kuk Young G&M Co. Ltd
KQ:006050
|
0.009x |
Annual Cash Flow Conversion Efficiency for Opthea Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Opthea Ltd from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see OPT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-201.07 Million ≈ $-142.27 Million |
AU$-158.64 Million ≈ $-112.25 Million |
0.789x | -62.85% |
| 2024-06-30 | AU$-75.81 Million ≈ $-53.64 Million |
AU$-161.02 Million ≈ $-113.93 Million |
2.124x | -89.58% |
| 2023-06-30 | AU$-8.79 Million ≈ $-6.22 Million |
AU$-179.30 Million ≈ $-126.87 Million |
20.391x | +1546.31% |
| 2022-06-30 | AU$69.77 Million ≈ $49.37 Million |
AU$-98.37 Million ≈ $-69.60 Million |
-1.410x | -316.10% |
| 2021-06-30 | AU$180.20 Million ≈ $127.50 Million |
AU$-61.06 Million ≈ $-43.20 Million |
-0.339x | -166.36% |
| 2020-06-30 | AU$64.81 Million ≈ $45.86 Million |
AU$-8.24 Million ≈ $-5.83 Million |
-0.127x | +83.63% |
| 2019-06-30 | AU$31.12 Million ≈ $22.02 Million |
AU$-24.19 Million ≈ $-17.11 Million |
-0.777x | -48.80% |
| 2018-06-30 | AU$38.17 Million ≈ $27.01 Million |
AU$-19.94 Million ≈ $-14.11 Million |
-0.522x | -370.79% |
| 2017-06-30 | AU$54.49 Million ≈ $38.56 Million |
AU$-6.05 Million ≈ $-4.28 Million |
-0.111x | +54.86% |
| 2016-06-30 | AU$14.98 Million ≈ $10.60 Million |
AU$-3.68 Million ≈ $-2.60 Million |
-0.246x | +18.54% |
| 2015-06-30 | AU$16.66 Million ≈ $11.79 Million |
AU$-5.03 Million ≈ $-3.56 Million |
-0.302x | +28.69% |
| 2014-06-30 | AU$9.87 Million ≈ $6.98 Million |
AU$-4.17 Million ≈ $-2.95 Million |
-0.423x | +1.23% |
| 2013-06-30 | AU$13.10 Million ≈ $9.27 Million |
AU$-5.61 Million ≈ $-3.97 Million |
-0.428x | -23.41% |
| 2012-06-30 | AU$20.67 Million ≈ $14.62 Million |
AU$-7.17 Million ≈ $-5.08 Million |
-0.347x | +14.02% |
| 2011-06-30 | AU$23.32 Million ≈ $16.50 Million |
AU$-9.42 Million ≈ $-6.66 Million |
-0.404x | -44.72% |
| 2010-06-30 | AU$27.04 Million ≈ $19.13 Million |
AU$-7.54 Million ≈ $-5.34 Million |
-0.279x | -32.46% |
| 2009-06-30 | AU$31.29 Million ≈ $22.14 Million |
AU$-6.59 Million ≈ $-4.66 Million |
-0.211x | -475.98% |
| 2008-06-30 | AU$49.18 Million ≈ $34.80 Million |
AU$-1.80 Million ≈ $-1.27 Million |
-0.037x | -105.73% |
| 2007-06-30 | AU$51.71 Million ≈ $36.59 Million |
AU$32.97 Million ≈ $23.33 Million |
0.638x | +1028.75% |
| 2006-06-30 | AU$42.07 Million ≈ $29.77 Million |
AU$-2.89 Million ≈ $-2.04 Million |
-0.069x | -20.11% |
| 2005-06-30 | AU$28.63 Million ≈ $20.26 Million |
AU$-1.64 Million ≈ $-1.16 Million |
-0.057x | +2.50% |
| 2004-06-30 | AU$29.15 Million ≈ $20.63 Million |
AU$-1.71 Million ≈ $-1.21 Million |
-0.059x | -31.10% |
| 2002-06-30 | AU$23.28 Million ≈ $16.47 Million |
AU$-1.04 Million ≈ $-736.53K |
-0.045x | -7.66% |
| 2001-06-30 | AU$24.20 Million ≈ $17.12 Million |
AU$-1.01 Million ≈ $-711.19K |
-0.042x | +87.30% |
| 1997-06-30 | AU$5.32 Million ≈ $3.77 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.327x | -3.21% |
| 1996-06-30 | AU$3.83 Million ≈ $2.71 Million |
AU$-1.22 Million ≈ $-859.69K |
-0.317x | +2.21% |
| 1995-06-30 | AU$2.07 Million ≈ $1.47 Million |
AU$-672.00K ≈ $-475.48K |
-0.324x | -44.64% |
| 1994-06-30 | AU$2.09 Million ≈ $1.48 Million |
AU$-469.00K ≈ $-331.85K |
-0.224x | -3.14% |
| 1993-06-30 | AU$1.62 Million ≈ $1.14 Million |
AU$-351.00K ≈ $-248.35K |
-0.217x | -32.60% |
| 1992-06-30 | AU$1.63 Million ≈ $1.15 Million |
AU$-267.00K ≈ $-188.92K |
-0.164x | -7.51% |
| 1991-06-30 | AU$1.29 Million ≈ $914.88K |
AU$-197.00K ≈ $-139.39K |
-0.152x | -- |
About Opthea Ltd
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more